PIK3CD and glioblastoma: These data show that collectively, first generation mTORC1 inhibitors do not benefit glioblastoma patients, likely due to feedback loops in the PI3K/AKT/mTOR signalling network, mainly from mTORC2 and AKT activation, which are not blocked by these rapalogs.